Searle & Co. Heron Therapeutics, Inc. Transaction History
Searle & Co.
- $390 Million
- Q1 2024
A detailed history of Searle & Co. transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Searle & Co. holds 86,250 shares of HRTX stock, worth $238,912. This represents 0.06% of its overall portfolio holdings.
Number of Shares
86,250
Previous 85,250
1.17%
Holding current value
$238,912
Previous $144,000
65.28%
% of portfolio
0.06%
Previous 0.04%
Shares
15 transactions
Others Institutions Holding HRTX
# of Institutions
168Shares Held
119MCall Options Held
151KPut Options Held
103K-
Rubric Capital Management LP New York, NY26.7MShares$74 Million2.52% of portfolio
-
Orbimed Advisors LLC San Diego, CA10.1MShares$28 Million0.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.11MShares$22.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$20.2 Million0.0% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$19.4 Million21.7% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $329M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...